comparemela.com
Latest Breaking News On - Riovant - Page 1 : comparemela.com
Roivant: Oral Brepocitinib Fails To Meet Primary Endpoint In Phase 2 Study
Roivant (ROIV) and Priovant announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 at Week 52.
Matt-gline
More-such-health-news
Systemic-lupus-erythematosus-responder-index
Systemic-lupus-erythematosus
Roivant
Riovant
vimarsana © 2020. All Rights Reserved.